Compare Allegion PLC (ALLE) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Boston Scientific Corporation — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Boston Scientific Corporation trades at $45 (market cap $66.54B). The key difference: Boston Scientific Corporation is far larger — about 5.7× Allegion PLC's market cap, and Allegion PLC pays a 1.55% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ALLE | BSX | |
|---|---|---|
Market Cap | $11.74B | $66.54B |
Sector | Industrials | Health |
52-Week High | $179.77 | $108.14 |
52-Week Low | $125.65 | $42.68 |
Enterprise Value | $13.46B | $76.12B |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
Boston Scientific (BSX) trades at $44.77, down 0.49% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $12.7B in 2022 to $20.1B in 2025, with net income margin expanding to 17.29%. Recent earnings beats and a 88% analyst buy rating contrast with the stock's 60% decline from its 2025 high, creating a significant valuation gap versus the $72.38 consensus target.
BSX presents a compelling value opportunity with attractive valuation metrics (P/E 18.73, P/S 3.25) and strong profitability, though investors face near-term technical weakness and competitive pressures in key segments like electrophysiology. The stock's current price represents a 38% discount to analyst targets, suggesting substantial upside potential for patient investors despite recent market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
